The Effects of Broadly Neutralizing Antibodies in Experimental HCV Infection

Abstract

Hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the US. The graft is universally infected after transplantation, and this typically results in accelerated fibrosis progression. Current HCV therapies have poor efficacy and tolerability in the challenging pre- and posttransplant populations. Alternative pre- and post-transplantation measures are needed to prevent graft infection. One potential strategy to prevent such infection is the administration of potent broadly neutralizing antibodies (bnAbs).

Additional details